Brian Abrahams an analyst at the investment firm RBC Capital Markets wrote in a recent note to clients how bottlenecks that have hindered sales of antiamyloid drugs  including screening and monitoring of patients  should mostly be alleviated by the time subcutaneous Leqembi could enter the market